Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sequana Medical NV is a commercial-stage medical device company specializing in innovative treatments for drug-resistant fluid overload, a critical complication in patients with liver disease, heart failure, and cancer. This condition, affecting a growing patient population where standard diuretics fail, leads to excess fluid buildup—up to 15 liters—resulting in heightened mortality, frequent hospitalizations, severe pain, breathing difficulties, and mobility limitations. The company’s proprietary platforms include the alfa pump system, a fully implanted wireless device that automatically transfers abdominal fluid to the bladder for natural elimination, approved by the US FDA in December 2024 for recurrent or refractory ascites due to liver cirrhosis and holding CE mark in Europe. Over 1,000 alfa pump devices have been implanted globally, demonstrating clinical benefits and cost savings for healthcare systems. In development is Direct Sodium Removal (DSR) therapy, targeting systemic fluid overload, with promising early results from studies like MOJAVE. Founded in 2006 and headquartered in Ghent, Belgium, Sequana Medical NV operates in the healthcare sector with about 62 employees, focusing on expanding commercialization, particularly in the US liver transplant centers.
€0.61
+€0.00 (+0.00%)
Price from 2 days ago
The business is unprofitable at the operating level (-17273.01% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 85.2% YoY. Margins deteriorated 13220.3pp alongside, both lines moving the wrong way.
Negative free cash flow of -€20M. The business is consuming cash, not generating it. Operating margin contracted 13220.3pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€106K
▼ -85.2% YoY
Net Income (TTM)
-€45M
▼ -37.1% YoY
Op. Margin
-17273.01%
▼ -13220.3pp YoY
ROIC
-49.96%
▲ +79.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€20M
▲ +31.6% YoY
Op. Cash Flow (TTM)
-€18M
▲ +38.1% YoY
Net Debt
€36M
Cash & Equiv.
€4M
3Y CAGR: -34.2%
Continue Research
Sequana Medical NV (SEQUA.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sequana Medical NV scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Sequana Medical NV scores 0 out of 100 on Intrinsiqq's quality score, passing 0 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -17,273.0% operating margin and a -50.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SEQUA.XBRU's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.